Skip to main content
. 2020 Jul 9;12:192. doi: 10.3389/fnagi.2020.00192

Figure 4.

Figure 4

Zonisamide attenuates the accumulation of Aβ and the phosphorylation of Tau in HFD/STZ-induced type 2 diabetic mice. Aβ was detected by Immunofluorescence in the external pyramidal layer (layer III) of the cerebral cortex. PHF1 and total Tau expression in the hippocampus and cortex were analyzed using Western blot. PHF1/Tau-5 expression was increased both in the hippocampus and cortex of T2DM mice, and the staining of Aβ was increased both in the superior and lateral cortex, while Zonisamide treatment attenuated Tau and Aβ alterations. (A) Immunofluorescent staining of Aβ (Green) and 4′,6-diamidino-2-phenylindole (DAPI; blue) in the superior and lateral cortex (scale bar = 50 μm). (B) Mean fluorescence intensity analysis for Aβ (n = 3 per group). (C) PHF1 and Tau-5 expression in the cortex and hippocampus. (D) The quantitative analysis of PHF1 using Tau-5 as normalization, respectively. Data are presented as the mean ± SEM (n = 4–5 mice). *P < 0.05, **P < 0.01 vs. Con; #P < 0.05, ##P < 0.01 vs. T2DM.